Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13217467 | 0.87 | ALDH1A1 (0.46) | DPP4CHRM1PIM1ALDH1A1 | |
| SCHEMBL13200737 | 0.86 | DPP4 (0.63) | DPP4CHRM1 | |
| SCHEMBL13200873 | 0.85 | DPP4 (0.56) | DPP4CHRM1PIM1HTR3A | |
| SCHEMBL13217690 | 0.84 | PIM1 (0.49) | DPP4CHRM1PIM1L3MBTL1HTR3A | |
| SCHEMBL13217456 | 0.84 | HTR3A (0.56) | DPP4CHRM1HTR3AALDH1A1 | |
| SCHEMBL13217595 | 0.83 | DPP4 (0.50) | DPP4CHRM1PIM1L3MBTL1HTR3A | |
| SCHEMBL13217596 | 0.83 | DPP4 (0.50) | DPP4CHRM1PIM1ALDH1A1 | |
| SCHEMBL13217421 | 0.82 | MEN1 (0.48) | DPP4CHRM1PIM1ALDH1A1POLB | |
| SCHEMBL13217574 | 0.81 | HTR2C (0.53) | DPP4CHRM1HTR3AALDH1A1 | |
| SCHEMBL13217883 | 0.81 | DPP4 (0.50) | DPP4CHRM1PIM1HTR3APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | DPP4 1/4885CHRM1 43/4885PIM1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.